GPI

Glucose-6-phosphate isomerase UniProt accession P06744

Isomerase that catalyzes the conversion of alpha-D-glucose-6-phosphate to beta-D-fructose-6-phosphate, the second step in glycolysis, and the reverse reaction in gluconeogenesis, within the cytoplasm (PubMed:28803808). Also shows C2-epimerase activity, interconverting D-glucose-6-phosphate (G6P) and D-mannose-6-phosphate (M6P) (By similarity). Also displays anomerase activity, interconverting alpha and beta-anomeric forms of G6P, D-fructose-6-phosphate and M6P (By similarity).

In addition to its metabolic role, this enzyme functions extracellularly as a cytokine: acts as autocrine motility factor (AMF), a secreted angiogenic factor that enhances endothelial cell motility (PubMed:11437381). Functions as neuroleukin, a neurotrophic factor supporting the survival of spinal and sensory neurons (PubMed:11004567, PubMed:3352745). Released by lectin-stimulated T-cells to induce immunoglobulin secretion (PubMed:11004567, PubMed:3352745)

Source: UniProt

Homodimer; in the catalytically active form (PubMed:11371164, PubMed:12054796, PubMed:12777791). Monomer in the secreted form (PubMed:11371164, PubMed:12054796, PubMed:12777791)

Source: UniProt
Cytoplasm, Secreted
Source: UniProt
  • Anemia, congenital, non-spherocytic hemolytic, 4 (CNSHA4)

    An autosomal recessive form of anemia in which there is no abnormal hemoglobin or spherocytosis. It is caused by glucose phosphate isomerase deficiency.

Source: UniProt
  • TP53 Regulates Metabolic Genes
  • Neutrophil degranulation
  • Glycolysis
  • Gluconeogenesis
Source: Reactome via UniProt

Mutations

No mutation information available.

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to GPI, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 40

NCT ID Condition Brief Title Phase Status
NCT04255719 Parkinson Disease, Deep Brain Stimulation, Globus Pallidus Interna, Subthalamic Nucleus Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD NA COMPLETED
NCT07092995 Parkinson&Amp;#39;s Disease, Freezing of Gait, Freezing of Gait Symptoms in Parkinson&Amp;#39;s Disease Understanding Freezing of Gait Using Brain Signals and Virtual Reality NA ENROLLING_BY_INVITATION
NCT00090376 Impotence, Prostate Cancer Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy PHASE2 COMPLETED
NCT00360009 Parkinson Disease Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease NA COMPLETED
NCT04618887 Meige Syndrome, Meigs Syndrome, Meige Disease, Meig Syndrome, Blepharospasm, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm of Both Eyelids, Blepharospasm Oromandibular Dystonia A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome N/A UNKNOWN
NCT07130162 Breast Cancer Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein in Breast Cancer N/A NOT_YET_RECRUITING
NCT00108511 Hypertriglyceridemia Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1 COMPLETED
NCT00331669 Dystonia, Movement Disorder Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia PHASE2 UNKNOWN
NCT01870518 Parkinson's Disease, Mild Cognitive Impairment, Dementia Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI NA TERMINATED
NCT02438033 Parkinson's Disease Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease PHASE1 WITHDRAWN